Gain-of-function mutations of the receptor tyrosine kinase KIT play a key role in the pathogenesis of systemic mastocytosis (SM), gastrointestinal stromal tumors (GIST) and some cases of acute myeloid leukemia (AML). Whereas KIT juxtamembrane domain mutations seen in most GIST cases are highly sensitive to imatinib, the kinase activation loop mutant D816V, frequently encountered in SM, hampers the binding ability of imatinib. We investigated the inhibitory activity of the novel tyrosine kinase inhibitor EXEL-0862 against two subclones of HMC-1 (human mast leukemia) cells, HMC-1.1 harboring the juxtamembrane domain mutation V560G, and HMC-1.2 carrying both V560G and the activation loop mutation D816V encountered in more than 80% of SM cases. EXEL-0862 inhibited the phosphorylation of KIT in a dose-dependent manner and decreased cell proliferation in both mast cell lines with higher activity against HMC-1.2 cells. Second, phosphorylation of KIT-dependent signals transducer and activator of transcription-3 (STAT3) and -5 (STAT5) was abrogated upon exposure to nanomolar EXEL-0862 concentrations. In addition, EXEL-0862 induced a time-and dosedependent proapoptotic effect in both mast cell lines and caused a significant reduction in mast cell content in bone marrow samples from patients with SM harboring D816V as well as from those without D816V mutation. We conclude that EXEL-0862 is active against KIT activation loop mutants and is a promising candidate for the treatment of patients with SM and other KITdriven malignancies harboring active site mutations.
Introduction
Systemic mastocytosis (SM) is characterized by a clonal proliferation of mast cells in the bone marrow, spleen, and other extracutaneous organs. 1 Both indolent and aggressive disease variants have been described. 2 Clinically, SM can manifest with mediator-related symptoms or organomegaly. In patients with aggressive disease variants, signs of organ dysfunction caused by mast cell infiltration are present. Patients with indolent SM (ISM) can be treated successfully using anti-mediator drugs. By contrast, patients with aggressive SM (ASM) or mast cell leukemia (MCL) are candidates for cytoreductive or targeted drugs. Current therapy of ASM and MCL include interferon-alpha and cladribine, but their efficacy is limited and the prognosis of patients remains poor. 3 Nearly all patients with SM harbor the activating oncogenic mutation KIT D816V that involves the substitution of an aspartic residue at codon 816 of the activation loop with a valine residue. This mutation promotes receptor autophosphorylation without the requirement of stem cell factor (SCF) stimulation. [4] [5] [6] [7] KIT is a 145 kDa transmembrane receptor tyrosine kinase of the type III subgroup characterized by 5 extracellular immunoglobulin-like domains and a split tyrosine kinase domain. 8 KIT-dependent cell types include mast cells, hematopoietic stem cells, germ cells, melanocytes, and interstitial cells of Cajal, among others. [8] [9] [10] Upon binding of SCF to the extracellular immunoglobulin-like domains, KIT undergoes homodimerization and autophosphorylation at the Y568 and Y570 tyrosine residues of the juxtamembrane domain.
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This leads to the phosphorylation and activation of multiple signaling pathways such as Janus kinase/signal transducer and activators of transcription (Jak-STAT), Src kinases, mitogenactivated protein (MAP) kinases, and phosphatidylinositol-3 (PI3) kinase. 11 Gain-of-function point mutations in the KIT kinase domain result in ligand-independent constitutive activation of
For personal use only. on . by guest www.bloodjournal.org From KIT signaling, which leads to uncontrolled cell proliferation and resistance to apoptosis. 12 Activation of the KIT tyrosine kinase by somatic mutation has been documented in a variety of human malignancies including SM, acute myeloid leukemia (AML), and gastrointestinal stromal tumors (GIST). 9 Several small molecule tyrosine kinase inhibitors such as imatinib and SU5614 have shown activity against the tyrosine kinase activity of wild-type and some KIT mutants. [13] [14] [15] However, the inhibitory effect of these agents depends greatly upon the nature of the KIT mutant isoform. For instance, imatinib has been associated with sustained objective responses in more than 50% of patients with metastatic GIST bearing the juxtamembrane KIT mutation V560G. 15, 16 However, mutations mapping to the KIT kinase domain 17 render imatinib completely ineffective. 18 The latter are best exemplified by the D816V mutation, which involves the substitution of aspartate to valine in codon 816 in the activation loop 17 lying at the entrance to the KIT enzymatic pocket, thus interfering with imatinib-binding. 18 Neither imatinib 18 nor the chemically-related tyrosine kinase inhibitor AMN107, 13 have significant in vitro activity against the D816V KIT mutants. Thus, drugs specifically targeting the D816V KIT mutant hold great promise for the treatment of neoplastic disorders harboring this mutation.
We report herein that the novel tyrosine kinase inhibitor EXEL-0862 kills mast cell lines harboring the juxtamembrane V560G KIT mutant, and significantly more those bearing the imatinib-resistant kinase domain D816V KIT mutation, as well as bone marrow mast cells from patients with SM. Furthermore, EXEL-0862 exerts a strong inhibitory effect on the KITdependent downstream signaling pathways STAT3 and STAT5 and induces apoptosis in human mast cells harboring D816V KIT mutant isoform.
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Materials and Methods

Reagents and antibodies
EXEL
Apoptosis assay
To determine the proportion of apoptotic HMC- Sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) and immunobloting were described previously. 20 
Immunoprecipitation
Immunoprecipitation was carried out according to the methods described previously. 21 In brief, total cell lysates obtained from control or treated cells were mixed with 3 µg of mouse anti-human KIT (CD117) monoclonal antibody overnight at 4°C, followed by the addition of 50
µl of Protein-A/G agarose slurry, and incubated for 3 hours. The immunoprecipitated complex was washed three times and then subjected to Western blotting. reaction and restriction fragment length polymorphism analysis as described previously 21, 22 , and confirmed by direct sequencing in all patients. Mononuclear cells were cultured in Stem-Pro serum-free medium (Invitrogen) supplemented with recombinant human SCF (100 ng/ml) for 7 days in the presence or absence of EXEL-0862 and then stained with anti-CD117-phycoerythrin (PE) for 30 minutes and washed. Detection of mast cells was performed by detection of surface CD117 expression by flow cytometry as previously described. 21 
Statistical analysis
GraphPad Prism software (GraghPad Software, San Diego, CA) was used to conduct the statistical analysis. A p value of less than 0.05 was considered statistically significant.
Results
EXEL-0862 inhibits cell proliferation and KIT phosphorylation at nanomolar concentrations
Mutations within the activation loop of the KIT kinase lead to ligand-independent activation and increased catalytic activity of KIT. [8] [9] [10] EXEL-0862 is a novel kinase inhibitor optimized for activity against fibroblast growth factor receptors (FGFRs), vascular endothelial growth factor receptors (VEGFRs), platelet derived growth factor receptors (PDGFRs), and FLT3 (Table 1) . EXEL-0862 is also a potent inhibitor of wild type KIT (IC 50 = 8.5 nM) and retains significant activity against recombinant KIT bearing the D816V mutation (IC 50 = 42 nM).
We examined the effect of EXEL-0862 on KIT phosphorylation in HMC-1.2 cells harboring the KIT loop activation mutant D816V that confers resistance to imatinib. The inability of imatinib to bind this mutant isoform is due to allosteric conflict between the imatinib structure and the open conformation of the KIT activation loop. HMC-1.1 cells harboring the juxtamembrane KIT V560G mutant are sensitive to imatinib and were used as a control.
We first investigated HMC-1.1 and HMC-1.2 cell viability upon exposure to EXEL-0862 by the MTS assay. Three independent samples were measured for each data point. Figure 1C ), which is consistent with previous reports demonstrating that the mutation D816V elicits KIT activation. 12 Treatment with EXEL-0862 decreased the phosphorylation of KIT in a concentration-dependent manner, indicating that EXEL-0862 substantially inhibited the activation of KIT in D816V-expressing cells. When the membrane was stripped and reprobed with anti-KIT antibody, we observed that the amount of total KIT was unchanged, suggesting that EXEL-0862 abolished KIT phosphorylation without altering KIT expression. Figure 2C ). Indirect immunofluorescence staining with anti-total STAT3 antibody ( Figure 2D ) revealed that STAT3 was localized in both cytoplasm and nucleus in control (starved) HMC-1.2 and HMC-1.1 cells, albeit dominantly in the cytoplasm. After stimulation with SCF and serum, STAT3 was mainly localized within the cell nuclei, as shown by its co-localization with the nuclear DAPI (4',6-diamidino-2-phenylindole) stain ( Figure 2D ). In contrast, following treatment with EXEL-0862 the majority of STAT3 remained localized to the cytoplasm, even after stimulation with SCF, suggesting that EXEL-0862 abrogated STAT3 nuclear translocation. In aggregate, these data suggest that EXEL-0862 exerts a potent inhibitory effect upon STAT3 and STAT5
phosphorylation that results in nuclear translocation inhibition.
EXEL-0862 induces apoptosis without significantly affecting cell cycle distribution
We next analyzed the capacity of EXEL-0862 to induce apoptosis in KIT mutant cell lines. When HMC-1.1 and HMC-1.2 cells were exposed to escalating doses of EXEL-0862 a dose-dependent specific cleavage of PARP, which is widely accepted as a specific marker of apoptosis, was observed ( Figure 3A) . Figure   5D ). Overall, these data suggest that EXEL-0862 may trigger apoptosis of mast cells through direct mitochondrial damage with release of cytochrome c and caspase activation.
Ex vivo effect of EXEL-0862 on primary mast cells from patients with SM
The 
Figure 4
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